Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Plans At-Risk Launch Of Mircera, But Offers Amgen A 20% Royalty

Executive Summary

Roche plans to move forward with an at-risk launch of Mircera (epoetin beta) if it does not receive a judicial ruling on its proposal to sell the anti-anemia drug at a reduced cost and pay Amgen a 20 percent royalty on sales. The company wants a court decision by the end of February

You may also be interested in...



Amgen v. Roche: Mircera Battle Continues In Court And At Trade Commission

Roche has agreed to the conditions set by a federal judge for the launch of its anti-anemia drug Mircera (epoetin beta) in the U.S

Amgen v. Roche: Mircera Battle Continues In Court And At Trade Commission

Roche has agreed to the conditions set by a federal judge for the launch of its anti-anemia drug Mircera (epoetin beta) in the U.S

Court May Ask Roche To Pay Amgen 22.5 Percent Royalty To Market Mircera

A district court judge issued a preliminary injunction blocking Roche's launch of Mircera (epoetin beta) in the United States and suggested the terms under which Roche might begin selling its anti-anemia drug

Related Content

UsernamePublicRestriction

Register

PS049297

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel